Northwest Biotherapeutics develops personalized immune therapies for cancer using the DCVax platform technology. Lead product DCVax-L treats Glioblastoma multiforme brain cancer after completing Phase III clinical trials. Another product, DCVax-Direct, is in Phase I/II trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | 100.0% |
| Net Debt/EBITDA | 100.0 |